One of the most debated topics of recent years is that relating to possibles side effects of the vaccines anti-COVID-19. In the last few hours, a new study on the safety of vaccinations. Under the magnifying glass the incidence of some adverse events such as thrombosis, pericarditis and myocarditis recorded on a basis of 99 million vaccinated. The research is the largest carried out on vaccines against Coronavirus.
The details of the study
The Global Vaccine Data Network (GVDN) through the Global COVID Vaccine Safety project evaluated the incidence rates of 13 heart, blood and neurological conditions comparing those following vaccination and those expected without the vaccine. Under analysis how much vaccines have increased the risk by looking for so-called “safety signals”.
The teacher Kristýna Faksová from the Department of Epidemiological Research at the Statens Serum Institut in Copenhagen (Denmark) led the research, stating that “the size of the population in this study increased the possibility of identifying rare potential safety signals of the vaccine. Individual sites or regions are unlikely to have a population large enough to detect very rare signals.”
The 13 conditions were also related to the type of vaccine used. It was discovered that within 42 days of vaccination the risk was very similar to the background risk i.e. that expected without vaccine in the general population for most of the conditions examined. There are some significant differences precisely due to the amount of vaccinated people analyzed. Pericarditis and myocarditis increased. In the case of the mRNA vaccine, the risk of pericarditis went from 1.74 times after the first dose to 2.64 times after the fourth dose, while for myocarditis the risk increased from 3.48 times after the first dose to 6. 10 after the second with the same mRNA vaccine. With regard to thrombosis of the cerebral venous sinus following the first dose of the viral vector vaccine, the risk was more than 3 times higher: 69 cases against the expected 21. The danger also increased after an mRNA vaccine (1.49 times after the first dose and 1.25 times after the second). There were 190 recorded cases of Guillain-Barré syndrome among people who received the viral vector vaccine compared to 66 without the vaccination.
